Cargando…

Should anti-CD20 be used as an immune reconstitution therapy?

Detalles Bibliográficos
Autores principales:	Smets, Ide, Wokke, Beatrijs, Smolders, Joost
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925887/ https://www.ncbi.nlm.nih.gov/pubmed/35822293 http://dx.doi.org/10.1177/13524585221109386

Ejemplares similares

Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model
por: Smets, Ide, et al.
Publicado: (2023)

Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment
por: Bruijstens, Arlette L, et al.
Publicado: (2020)

Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis
por: Blok, Katelijn M., et al.
Publicado: (2023)

Distinct Effector Programs of Brain-Homing CD8(+) T Cells in Multiple Sclerosis
por: Koetzier, Steven C., et al.
Publicado: (2022)

Presymptomatic MS or radiologically isolated syndrome (RIS) should be actively monitored and treated – NO
por: Smets, Ide
Publicado: (2023)

Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapses
por: Janssen, Malou, et al.
Publicado: (2020)

Functional Immune Reconstitution by Interleukin-2 Adjunctive Therapy for HIV/Mycobacterial Co-infection
por: Heyckendorf, Jan, et al.
Publicado: (2015)

IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER USE OF ANTI-RETROVIRAL THERAPY IN COVID-19
por: NANGRANI, KUNAL, et al.
Publicado: (2021)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Anti-CD20 should be the first-line treatment in high-risk membranous nephropathy
por: Zand, Ladan, et al.
Publicado: (2023)

Screening of the transcriptional regulatory regions of vascular endothelial growth factor receptor 2 (VEGFR2) in amyotrophic lateral sclerosis
por: Brockington, Alice, et al.
Publicado: (2007)

Immune reconstitution inflammatory syndrome in a unique clinical scenario
por: Anubhav, G., et al.
Publicado: (2010)

Leprosy as Immune Reconstitution Inflammatory Syndrome in HIV-positive Persons
por: Martiniuk, Frank, et al.
Publicado: (2007)

Worsening acute respiratory distress syndrome: Is it immune reconstitution inflammatory syndrome?
por: Saroa, Richa, et al.
Publicado: (2013)

Pulsed immune reconstitution therapy in multiple sclerosis
por: Sorensen, Per Soelberg, et al.
Publicado: (2019)

Multiple sclerosis: why we should focus on both sides of the (auto) antibody
por: den Dunnen, Jeroen, et al.
Publicado: (2021)

Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm
por: Panoskaltsis, Nicki, et al.
Publicado: (2020)

Tuberculosis and human immunodeficiency virus coinfection complicated by immune reconstitution inflammatory syndrome
por: Barman, Bhupen, et al.
Publicado: (2022)

Long term immune reconstitution after immunoablation and autologous CD34 cell therapy in autoimmune diseases
por: Thiel, AT, et al.
Publicado: (2002)

Immune reconstitution inflammatory syndrome, with pulmonary and neurological cryptococcosis, in an HIV-negative patient
por: Queiroz, Rodolfo Mendes, et al.
Publicado: (2016)

The aware, alert, avert strategy for immune reconstitution inflammatory syndrome in HIV/AIDS
por: Grewal, Udhayvir Singh
Publicado: (2017)

Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy
por: Bazzi, Sam A., et al.
Publicado: (2022)

How frequently should asymptomatic patients be dilated? 20-year results
por: Varner, Paul
Publicado: (2019)

B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4(+) T cell responses in highly sensitized transplant recipients
por: Tanaka, Asuka, et al.
Publicado: (2021)

Fatigue is part of the burden of neuromuscular diseases
por: Wokke, J. H. J.
Publicado: (2007)

Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies
por: Cooles, Faye A. H., et al.
Publicado: (2016)

Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
por: Wang, Ying, et al.
Publicado: (2021)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Programmed Cell Death Protein 1–Positive CD8(+) T Cells in Multiple Sclerosis: Exhausted Fighters or Peacekeepers
por: Smolders, Joost, et al.
Publicado: (2022)

Anti‐cachexia therapy should target metabolism, inflammatory cytokines, and androgens in hormone‐independent cancers
por: Lambert, Charles Paul
Publicado: (2021)

Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients
por: Liebers, Nora, et al.
Publicado: (2022)

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial
por: Scarfò, Lydia, et al.
Publicado: (2022)

Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide
por: Espinoza-Gutarra, Manuel, et al.
Publicado: (2023)

Gut immune reconstitution in immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome after hematopoietic stem cell transplantation
por: Gambineri, Eleonora, et al.
Publicado: (2015)

Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies
por: Friedli, Christoph, et al.
Publicado: (2021)

Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence
por: Nachega, Jean B, et al.
Publicado: (2012)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Anti-SARS-CoV-2 humoral and cellular responses in multiple sclerosis patients treated with anti-CD20 monoclonal antibodies
por: Nicolas, Philippe, et al.
Publicado: (2022)

THE IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME
por: Bosamiya, Sanjay S
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_1nvdtts7501552lv7kh3v7tchs